A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01308723
First received: March 2, 2011
Last updated: August 4, 2014
Last verified: August 2014

March 2, 2011
August 4, 2014
March 2011
January 2012   (final data collection date for primary outcome measure)
  • Part I : Safety/dose-limiting toxicity: Incidence of adverse events [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
  • Part I: Determination of recommended Part II dose [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
  • Part II: Safety/tolerability: Incidence of adverse events [ Time Frame: up to 28 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01308723 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics of RO5323441 in combination with sorafenib [ Time Frame: up to 40 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics of sorafenib in combination with RO5323441 [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
  • Pharmacodynamic biomarkers (DCE-Magnetic Resonance Imaging evaluations, Placental Growth Factor, Vascular Endothelial Growth Factor Receptors) [ Time Frame: up to 40 months ] [ Designated as safety issue: No ]
  • Efficacy: tumor assessments by Magnetic Resonance Imaging or Computed Tomography according to RECIST criteria [ Time Frame: up to 40 months ] [ Designated as safety issue: No ]
  • Impact on wound healing (skin biopsies) [ Time Frame: up to 40 months ] [ Designated as safety issue: No ]
  • Safety: additional anti-drug antibodies sampling after termination of study drug treatment [ Time Frame: 2 and 4 months after last dose of study drug ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
Exploratory Open Label Dose-escalation Phase Ib Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO5323441, Administered Intravenously, in Combination With Sorafenib (Nexavar®), in Patients With Advanced or Metastatic and/or Unresectable Hepatocellular Carcinoma

This open-label study will assess the safety, efficacy and pharmacokinetics of R O5323441 in combination with sorafenib in patients with advanced or metastatic h epatocellular carcinoma previously untreated with systemic therapy. In the dose- finding Part I, cohorts of patients will receive escalating doses of RO5323441 i ntravenously (iv) every 2 weeks in combination with sorafenib 400 mg orally twic e daily. In the exploratory Part II, patients will be randomized to receive eith er the previously established dose of RO5323441 iv every 2 weeks plus continuous oral sorafenib or sorafenib alone. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs. For patients in the sorafe nib arm with disease progression crossover to combination treatment with RO53234 41 will be allowed.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Liver Cancer
  • Drug: RO5323441
    escalating doses iv
  • Drug: RO5323441
    iv every 2 weeks
  • Drug: sorafenib
    400 mg orally twice daily to once every other day
  • Experimental: Part I
    Interventions:
    • Drug: RO5323441
    • Drug: sorafenib
  • Experimental: Part II (A)
    Interventions:
    • Drug: RO5323441
    • Drug: sorafenib
  • Active Comparator: Part II (B)
    Intervention: Drug: sorafenib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6
January 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients >/= 21 years of age
  • Advanced or metastatic and/or unresectable hepatocellular carcinoma
  • At least 1 measurable lesion according to RECIST criteria
  • Primary tumor in situ (Expansion Cohort Part I, Part II)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Adequate bone marrow, liver and renal function

Exclusion Criteria:

  • Prior systemic treatment for metastatic hepatocellular carcinoma or patients who had tumor removed (Expansion Cohort Part I, Part II)
  • Major surgery within previous 4 weeks or planned major surgical procedure during course of study
  • Radiation therapy within 28 days prior to start of study treatment
  • Serious non-healing wound, ulcer ore bone fracture
  • History of uncontrolled seizures or encephalopathy within the last 6 months
  • Current central nervous system (CNS) metastases or spinal cord compression
  • History of gastrointestinal perforation or esophageal/gastric bleeding within 6 months prior to study enrollment
  • History of another primary malignancy and off treatment for </= 3 years, except for non-melanoma skin cancer and carcinoma in situ of the cervix
  • Patients with prior liver transplant
  • Inadequately controlled hypertension or prior history of hypertensive crisis or hypertensive encephalopathy
  • Active bleeding diathesis
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Singapore
 
NCT01308723
BP25497
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP